Form 4: BioLargo CFO Charles Dargan Acquires 300,000 Shares Via Option Grant
SEC Form 4 Filing
Charles K. Dargan, CFO of BioLargo, Inc., reports the acquisition of 300,000 shares through an option grant, vesting monthly, as part of his compensation.
Summary
- Charles K. Dargan, the Chief Financial Officer of BioLargo, Inc., filed a Form 4 on August 15, 2024, reporting a transaction that occurred on August 13, 2024.
- Dargan acquired 300,000 shares of BioLargo common stock through an option grant with an exercise price of $0.24.
- The option vests in equal monthly installments of 25,000 shares, contingent upon the continuation of the Engagement Extension Agreement between Dargan and BioLargo.
- This option was granted as compensation for Dargan's service as CFO from February 1, 2024, through January 31, 2025.
- Following the reported transaction, Dargan directly owns 4,625,786 derivative securities.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It is neutral in tone and does not contain information that would significantly impact investor sentiment positively or negatively.
Positives
- The option grant aligns the CFO's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and performance by the CFO.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Option grants are a common form of executive compensation in publicly traded companies, aligning management's interests with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including option grants, vary significantly across industries and company sizes.
- Comparing BioLargo's executive compensation to similar companies in the cleantech or biotechnology sectors would provide a more detailed assessment.
- Companies like Xometry, Inc. and Desktop Metal, Inc. have similar compensation packages for their executives.
Stakeholder Impact
- The option grant could potentially incentivize the CFO to improve company performance, benefiting shareholders.
- Employees may view the option grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2/14/2017 | Date of Limited Power of Attorney execution. |
| 02/01/2024 | Start date of Charles Dargan's CFO service for which the option was granted as compensation. |
| 08/13/2024 | Date of the option grant transaction. |
| 08/13/2024 | Option exercisable date. |
| 08/13/2034 | Option expiration date. |
| 08/15/2024 | Date of Form 4 filing. |
| 01/31/2025 | End date of Charles Dargan's CFO service for which the option was granted as compensation. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.